Inactive Instrument

Press Releases LogicBio Therapeutics, Inc.

Equities

LOGC

US54142F1021

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Alexion AstraZeneca Rare Disease Completes Acquisition of LogicBio Therapeutics	22-11-17	AQ
LOGICBIO THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	22-11-16	AQ
LogicBio Therapeutics : Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet - Definitive merger agreement with Alexion, AstraZeneca Rare Disease, to acquire LogicBio with transaction - Form 8-K	22-11-14	PU
LOGICBIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-14	AQ
LOGICBIO THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)	22-11-14	AQ
LogicBio Therapeutics: Q3 Earnings Snapshot	22-11-14	AQ
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates	22-11-14	PR
LOGICBIO THERAPEUTICS, INC. : Other Events (form 8-K)	22-10-20	AQ
LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC	22-10-18	BU
LOGICBIO THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)	22-10-07	AQ
LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC	22-10-04	BU
Alexion, AstraZeneca Rare Disease to Acquire LogicBio Therapeutics to Accelerate Growth in Genomic Medicine	22-10-04	AQ
LOGICBIO THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	22-10-03	AQ
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine	22-10-03	PR
LOGICBIO THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	22-09-23	AQ
LogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE	22-09-21	PR
LOGICBIO THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	22-09-20	AQ
LOGICBIO THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	22-09-16	AQ
LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update	22-08-16	AQ
LogicBio Therapeutics : Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Form 8-K	22-08-15	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases LogicBio Therapeutics, Inc.

Equities

LOGC

US54142F1021

Press Releases

Filters